Drugs / BI 3011441
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04835714 | Apr 2021 → Jan 2022 | — | Boehringer Ingelheim | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04742556 | Mar 2021 → Oct 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 3011441 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04742556 ↗ |
| Action | Inhibit | “BI 3011441 is a medicine that may turn off a signal by NRAS/KRAS that makes tumours grow.” NCT04742556 ↗ |
| Route | Oral | “Participants take BI 3011441 as capsules once a day.” NCT04742556 ↗ |
| Target | KRAS | “BI 3011441 is a medicine that may turn off a signal by NRAS/KRAS that makes tumours grow.” NCT04742556 ↗ |
| Target | NRAS | “BI 3011441 is a medicine that may turn off a signal by NRAS/KRAS that makes tumours grow.” NCT04742556 ↗ |